DE69619132T2 - Chimäre oligomere mit einer rns-spaltungsaktivität - Google Patents

Chimäre oligomere mit einer rns-spaltungsaktivität

Info

Publication number
DE69619132T2
DE69619132T2 DE69619132T DE69619132T DE69619132T2 DE 69619132 T2 DE69619132 T2 DE 69619132T2 DE 69619132 T DE69619132 T DE 69619132T DE 69619132 T DE69619132 T DE 69619132T DE 69619132 T2 DE69619132 T2 DE 69619132T2
Authority
DE
Germany
Prior art keywords
oligomers
chimeral
rns
rna
cleaving activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69619132T
Other languages
English (en)
Other versions
DE69619132D1 (de
Inventor
Janos Ludwig
Brian Sproat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VIMRX HOLDINGS Ltd
Original Assignee
VIMRX HOLDINGS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1995142404 external-priority patent/DE19542404A1/de
Application filed by VIMRX HOLDINGS Ltd filed Critical VIMRX HOLDINGS Ltd
Priority to DE69619132T priority Critical patent/DE69619132T2/de
Publication of DE69619132D1 publication Critical patent/DE69619132D1/de
Application granted granted Critical
Publication of DE69619132T2 publication Critical patent/DE69619132T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69619132T 1995-11-14 1996-11-14 Chimäre oligomere mit einer rns-spaltungsaktivität Expired - Fee Related DE69619132T2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE69619132T DE69619132T2 (de) 1995-11-14 1996-11-14 Chimäre oligomere mit einer rns-spaltungsaktivität

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE1995142404 DE19542404A1 (de) 1995-11-14 1995-11-14 Chimäre Oligomere mit RNA-Spaltungsaktivität
US61229896A 1996-03-07 1996-03-07
PCT/EP1996/005014 WO1997018312A1 (en) 1995-11-14 1996-11-14 Chimeric oligomers having an rna-cleavage activity
DE69619132T DE69619132T2 (de) 1995-11-14 1996-11-14 Chimäre oligomere mit einer rns-spaltungsaktivität

Publications (2)

Publication Number Publication Date
DE69619132D1 DE69619132D1 (de) 2002-03-21
DE69619132T2 true DE69619132T2 (de) 2002-07-18

Family

ID=26020354

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69619132T Expired - Fee Related DE69619132T2 (de) 1995-11-14 1996-11-14 Chimäre oligomere mit einer rns-spaltungsaktivität

Country Status (7)

Country Link
EP (1) EP0866865B1 (de)
JP (1) JP2000501284A (de)
AT (1) ATE213019T1 (de)
AU (1) AU7572096A (de)
CA (1) CA2237528A1 (de)
DE (1) DE69619132T2 (de)
WO (1) WO1997018312A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103890A (en) * 1994-05-18 2000-08-15 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids that cleave C-fos
US6610478B1 (en) 1996-08-16 2003-08-26 Yale University Phenotypic conversion of cells mediated by external guide sequences
US6300483B1 (en) * 1997-06-19 2001-10-09 Ribozyme Pharmaceuticals, Inc. Compositions inducing cleavage of RNA motifs
CA2295207A1 (en) * 1997-06-19 1998-12-23 Innovir Laboratories, Inc. Hammerhead ribozymes with extended cleavage rule
US6410225B1 (en) 1997-06-27 2002-06-25 Yale University Purification of oligomers
US20030165888A1 (en) 2001-07-18 2003-09-04 Brown Bob D. Oligonucleotide probes and primers comprising universal bases for diagnostic purposes
US6518017B1 (en) 1997-10-02 2003-02-11 Oasis Biosciences Incorporated Combinatorial antisense library
US6013447A (en) * 1997-11-21 2000-01-11 Innovir Laboratories, Inc. Random intracellular method for obtaining optimally active nucleic acid molecules
US6248525B1 (en) 1998-03-30 2001-06-19 Yale University Method for identifying essential or functional genes
AU5016200A (en) * 1999-05-21 2000-12-12 Myriad Genetics, Inc. Diabetes gene
US6902888B1 (en) 1999-05-21 2005-06-07 Myriad Genetics, Inc. Diabetes gene
EP1223950B1 (de) * 1999-10-26 2006-01-04 Immusol, Inc. Ribozym-therapie zur behandlung von proliferativen augenkranheiten
CA2425779C (en) 2000-10-12 2013-08-06 University Of Rochester Compositions that inhibit proliferation of cancer cells
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
KR20040096554A (ko) 2002-02-06 2004-11-16 비코르 테크놀로지스 인코포레이티드 경색방지 분자
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1432724A4 (de) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc Durch rna-interferenz vermittelte inhibierung von map-kinase-genen
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CA2495478A1 (en) 2002-08-05 2004-02-12 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
US8658377B2 (en) 2002-11-15 2014-02-25 Morehouse School Of Medicine Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
US8512701B2 (en) 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
US9233120B2 (en) 2002-11-15 2016-01-12 Jyant Technologies Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
JP5562521B2 (ja) 2005-02-02 2014-07-30 ザ ユーエービー リサーチ ファンデーション アポトーシス誘導デスレセプターアゴニストに対する抵抗性を低減することに関する薬剤及び方法
CN112480257A (zh) 2005-03-23 2021-03-12 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
EP2392647A1 (de) 2005-10-14 2011-12-07 MUSC Foundation For Research Development Targeting von PAX2 zur Induktion der DEFB1-vermittelten Tumorimmunität und Krebstherapie
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
JP5926475B2 (ja) 2006-09-21 2016-05-25 ユニバーシティー オブ ロチェスター 筋緊張性ジストロフィーのためのタンパク質置換治療に関する組成物および方法
US8999317B2 (en) 2006-11-01 2015-04-07 University Of Rochester Methods and compositions related to the structure and function of APOBEC3G
US9896511B2 (en) 2007-01-10 2018-02-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
US9068003B2 (en) 2007-01-10 2015-06-30 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
US8501912B2 (en) 2007-12-03 2013-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Filipil compositions and methods for treating cancer
EP2853897A1 (de) 2008-05-08 2015-04-01 University Of Utah Research Foundation Sensorische Rezeptoren für chronische Müdigkeit und Schmerzen und Verwendungen davon
WO2010065617A1 (en) 2008-12-02 2010-06-10 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
US20110060000A1 (en) 2009-09-10 2011-03-10 Maurizio Grimaldi Acridine analogs in the treatment of gliomas
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
US10723794B2 (en) 2015-03-18 2020-07-28 University Of South Carolina Anti-CcL8 antibodies and uses thereof
KR20190037273A (ko) 2016-08-03 2019-04-05 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 Tlr9 표적 치료제
US12016314B2 (en) 2017-09-08 2024-06-25 Ohio State Innovation Foundation MicroRNA inhibitor therapy in systemic lupus erythematosus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930701590A (ko) * 1990-06-19 1993-06-12 알프레드 퍼나트 엔도누클레아제
CA2093664C (en) * 1990-10-12 2003-07-29 Fritz Eckstein Modified ribozymes
US5652094A (en) * 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
EP0672133B1 (de) * 1992-11-03 2004-06-16 Gene Shears Pty Limited TNF-alpha RIBOZYME UND ABBAU-RESISTENTE mRNA DERIVATIVE GEBUNDEN AN TNF-alpha Ribozyme
GB9225427D0 (en) * 1992-12-04 1993-01-27 Ribonetics Gmbh Oligonucleotides with rna cleavage activity
US5861288A (en) * 1993-10-18 1999-01-19 Ribozyme Pharmaceuticals, Inc. Catalytic DNA

Also Published As

Publication number Publication date
CA2237528A1 (en) 1997-05-22
ATE213019T1 (de) 2002-02-15
DE69619132D1 (de) 2002-03-21
WO1997018312A1 (en) 1997-05-22
JP2000501284A (ja) 2000-02-08
EP0866865A1 (de) 1998-09-30
EP0866865B1 (de) 2002-02-06
AU7572096A (en) 1997-06-05

Similar Documents

Publication Publication Date Title
DE69619132D1 (de) Chimäre oligomere mit einer rns-spaltungsaktivität
DK0691980T3 (da) 7-deazapurinmodifiderende oligonukleotider
FI951612A (fi) Menetelmiä synteettisten oligonukleotidien sekvensoimiseksi, jotka sisältävät nukleotidien välisiä ei-fosfodiesterisidoksia
KR950703659A (ko) 보존된 g₄핵심서열을 갖는 올리고누클레오티드(oligonucleotioes having a conserved g₄core sequence)
WO1996019568A3 (en) Stabilized ribozyme analogs
ATE280772T1 (de) Antisense oligonukleotidmodulation der raf genexpression
ATE239090T1 (de) Methode zum generieren von einzelsträngigen dna molekülen
DK0517796T3 (da) Oligonukleotid-analoger
DE69514773D1 (de) Chimärisches Oligonukleotid und dessen Verwendung zur Herstellung von Nukleinsäure-Transkripten
DE69620906T2 (de) Antisense-oligonukleotidmodulation der raf-genexpression
CA2153254A1 (en) Cloning of enterokinase and method of use
ES2193144T3 (es) Compuestos de dna que comprenden secuencias que codifican manuronano c-5-epimerasa.
EP1123414A4 (de) Antisense modulation der expression von integrin alpha 4
WO2000029623A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
DE69308531D1 (de) Cycloisomaltooligosaccharide; Enzym und Verfahren zu ihrer Herstellung, und Verfahren zur Herstellung von dem Enzym
DK0840802T3 (da) Fremgangsmåde til sekvensering gennem oligomerhybridisering
DE3778158D1 (de) Inhibitoren von esterase produzierenden mikroorganismen zur hauptverwendung in deodorants.
WO2000029622A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
AU2001287860A1 (en) Transglutaminase gene products
ATE381615T1 (de) Nukleinsäure-enzym zur spaltung von rna
ATE74503T1 (de) Inhibitoren von esterase produzierenden mikroorganismen zur hauptverwendung in deodorants.

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee